Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.

Frey SE, Newman FK, Kennedy JS, Sobek V, Ennis FA, Hill H, Yan LK, Chaplin P, Vollmar J, Chaitman BR, Belshe RB.

Vaccine. 2007 Dec 12;25(51):8562-73. Epub 2007 Oct 26.

2.

Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model.

Garza NL, Hatkin JM, Livingston V, Nichols DK, Chaplin PJ, Volkmann A, Fisher D, Nalca A.

Vaccine. 2009 Sep 4;27(40):5496-504. doi: 10.1016/j.vaccine.2009.06.105. Epub 2009 Jul 24.

3.

Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.

Walsh SR, Wilck MB, Dominguez DJ, Zablowsky E, Bajimaya S, Gagne LS, Verrill KA, Kleinjan JA, Patel A, Zhang Y, Hill H, Acharyya A, Fisher DC, Antin JH, Seaman MS, Dolin R, Baden LR.

J Infect Dis. 2013 Jun 15;207(12):1888-97. doi: 10.1093/infdis/jit105. Epub 2013 Mar 12.

4.

Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Virology. 2005 Sep 1;339(2):164-75.

5.

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, Koup RA, Roederer M, Bailer RT, Moodie Z, Gu L, Yan L, Graham BS; VRC 201/203 Study Team.

Vaccine. 2007 Feb 9;25(8):1513-25. Epub 2006 Nov 7.

6.

IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.

Kennedy JS, Greenberg RN.

Expert Rev Vaccines. 2009 Jan;8(1):13-24. doi: 10.1586/14760584.8.1.13. Review.

PMID:
19093767
7.

Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.

Frey SE, Winokur PL, Salata RA, El-Kamary SS, Turley CB, Walter EB Jr, Hay CM, Newman FK, Hill HR, Zhang Y, Chaplin P, Tary-Lehmann M, Belshe RB.

Vaccine. 2013 Jun 24;31(29):3025-33. doi: 10.1016/j.vaccine.2013.04.050. Epub 2013 May 9.

8.

Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.

Seaman MS, Wilck MB, Baden LR, Walsh SR, Grandpre LE, Devoy C, Giri A, Noble LC, Kleinjan JA, Stevenson KE, Kim HT, Dolin R.

J Infect Dis. 2010 May 1;201(9):1353-60. doi: 10.1086/651560.

9.

Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.

Earl PL, Americo JL, Wyatt LS, Espenshade O, Bassler J, Gong K, Lin S, Peters E, Rhodes L Jr, Spano YE, Silvera PM, Moss B.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10889-94. doi: 10.1073/pnas.0804985105. Epub 2008 Aug 4.

10.

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.

Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E, Röesch S, von Krempelhuber A, Young P, Nichols R, Meyer TP, Schmidt D, Weigl J, Virgin G, Arndtz-Wiedemann N, Chaplin P.

PLoS One. 2016 Jun 21;11(6):e0157335. doi: 10.1371/journal.pone.0157335. eCollection 2016.

11.

Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.

Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, Schlereth B, Handley A, King L, Hülsemann V, Tzatzaris M, Merkl K, Wulff N, Chaplin P.

Vaccine. 2006 Mar 15;24(12):2065-70. Epub 2005 Nov 28.

PMID:
16337719
12.

Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.

Kennedy JS, Gurwith M, Dekker CL, Frey SE, Edwards KM, Kenner J, Lock M, Empig C, Morikawa S, Saijo M, Yokote H, Karem K, Damon I, Perlroth M, Greenberg RN.

J Infect Dis. 2011 Nov;204(9):1395-402. doi: 10.1093/infdis/jir527. Epub 2011 Sep 15.

13.

Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax.

Davies DH, Wyatt LS, Newman FK, Earl PL, Chun S, Hernandez JE, Molina DM, Hirst S, Moss B, Frey SE, Felgner PL.

J Virol. 2008 Jan;82(2):652-63. Epub 2007 Oct 31.

14.

Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs.

Hermanson G, Chun S, Felgner J, Tan X, Pablo J, Nakajima-Sasaki R, Molina DM, Felgner PL, Liang X, Davies DH.

Vaccine. 2012 Jan 11;30(3):614-25. doi: 10.1016/j.vaccine.2011.11.021. Epub 2011 Nov 17.

15.

Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults.

Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF, Monath TP.

Vaccine. 2009 Mar 4;27(10):1637-44. doi: 10.1016/j.vaccine.2008.11.079. Epub 2008 Dec 9.

PMID:
19071184
16.

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Wyatt LS, Earl PL, Eller LA, Moss B.

Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4590-5. Epub 2004 Mar 11.

17.

Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.

Perera LP, Waldmann TA, Mosca JD, Baldwin N, Berzofsky JA, Oh SK.

J Virol. 2007 Aug;81(16):8774-83. Epub 2007 Jun 6.

18.

Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.

Frey SE, Winokur PL, Hill H, Goll JB, Chaplin P, Belshe RB.

Vaccine. 2014 May 13;32(23):2732-9. doi: 10.1016/j.vaccine.2014.02.043. Epub 2014 Mar 6.

19.
20.

Supplemental Content

Support Center